Use of procalcitonin, C-reactive protein and white blood cell count to distinguish between lower limb erysipelas and deep vein thrombosis in the emergency department: A prospective observational study

Journal of Dermatology

Volumn 42, Issue 8, 2015, Pages 778-785

  Rast, Anna C ^a   Knobel, Demian ^a   Faessler, Lukas ^a   Kutz, Alexander ^a   Felder, Susan ^a   Laukemann, Svenja ^a   Steiner, Deborah ^a   Haubitz, Sebastian ^b   Fux, Christoph A ^a   Huber, Andreas ^a   Mueller, Beat ^a   Schuetz, Philipp ^a  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

cellulitis; deep vein thrombosis; erysipelas; lower limb; procalcitonin

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN; BIOLOGICAL MARKER; CALCITONIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DEEP VEIN THROMBOSIS; DIAGNOSTIC VALUE; DISEASE SEVERITY; EMERGENCY WARD; ERYSIPELAS; FEMALE; HUMAN; LEG; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POPULATION RISK; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; METABOLISM; MIDDLE AGED; VENOUS THROMBOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; C-REACTIVE PROTEIN; CALCITONIN; DIAGNOSIS, DIFFERENTIAL; ERYSIPELAS; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VENOUS THROMBOSIS;

EID: 84937976207     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12922     Document Type: Article

References (38)

1. Cox NH,. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol 2006; 155 (5): 947-950.
2. Roujeau JC, Sigurgeirsson B, Korting HC, et al,. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004; 209 (4): 301-307.
3. Halpern J, Holder R, Langford NJ,. Ethnicity and other risk factors for acute lower limb cellulitis: a U.K.-based prospective case-control study. Br J Dermatol 2008; 158 (6): 1288-1292.
4. Bjornsdottir S, Gottfredsson M, Thorisdottir AS, et al,. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis 2005; 41 (10): 1416-1422.
5. Mokni M, Dupuy A, Denguezli M, et al,. Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology 2006; 212: 108-112.
6. Dupuy A, Benchikhi H, Roujeau JC, et al,. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318 (7198): 1591-1594.
7. Gunderson CG, Martinello RA,. A systematic review of bacteremias in cellulitis and erysipelas. J Infect 2012; 64: 148-155.
8. Phoenix G, Das S, Joshi M,. Diagnosis and management of cellulitis. BMJ 2012; 345: e4955.
9. Stevens DL, Bisno AL, Chambers HF, et al,. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59: 147-159.
10. ten Cate-Hoek AJ, van der Velde EF, Toll DB, et al,. Common alternative diagnoses in general practice when deep venous thrombosis is excluded. Neth J Med 2012; 70 (3): 130-135.
11. van Gemmeren D, Fobbe F, Ruhnke-Trautmann M, et al,. Diagnosis of deep leg vein thrombosis with color-coded duplex sonography and sonographic determination of the duration of the thrombosis. Z Kardiol 1991; 80 (8): 523-528.
12. Tick LW, Ton E, van Voorthuizen T, et al,. Practical diagnostic management of patients with clinically suspected deep vein thrombosis by clinical probability test, compression ultrasonography, and D-dimer test. Am J Med 2002; 113 (8): 630-635.
13. Mazzolai L, Haesler E, Milesi I, et al,. D-dimers testing is not recommended for the exclusion of deep vein thrombosis in outpatients with lower limb erysipelas. Thromb Haemost 2002; 88 (5): 880.
14. Schuetz P, Aujesky D, Muller C, et al,. Biomarker-guided personalised emergency medicine for all-hope for another hype? Swiss Med Wkly 2015; 145: w14079.
15. Assicot M, Gendrel D, Carsin H, et al,. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341 (8844): 515-518.
16. Simon L, Gauvin F, Amre DK, et al,. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39 (2): 206-217.
17. Delevaux I, Andre M, Colombier M, et al,. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 2003; 62 (4): 337-340.
18. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al,. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363 (9409): 600-607.
19. Schuetz P, Christ-Crain M, Thomann R, et al,. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059-1066.
20. Schuetz P, Briel M, Christ-Crain M, et al,. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012; 55: 651-662.
21. Schuetz P, Kutz A, Grolimund E, et al,. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol 2014; 175 (3): 464-472.
22. Eder J, Hlavin G, Haushofer A, et al,. Correlation of serum procalcitonin with the severity of skin and skin structure infections-a pilot study. J Dtsch Dermatol Ges 2012; 10 (8): 564-571.
23. Zeng M, Guo Z, Shen S, et al,. Value of serum procalcitonin and interleukin-6 in patients with bullous impetigo and staphylococcal scalded skin syndrome. J Dermatol 2014; 41: 1028-1029.
24. Saeed K, Ahmad N, Dryden M,. The value of procalcitonin measurement in localized skin and skin structure infection, diabetic foot infections, septic arthritis and osteomyelitis. Expert Rev Mol Diagn 2014; 14 (1): 47-54.
25. Schuetz P, Hausfater P, Amin D, et al,. Optimizing triage and hospitalization in adult general medical emergency patients: the triage project. BMC Emerg Med 2013; 13: 12.
26. Hirschmann JV, Raugi GJ,. Lower limb cellulitis and its mimics: part II. Conditions that simulate lower limb cellulitis. J Am Acad Dermatol 2012; 67 (2): 177 e1-177 e9; quiz 85-86.
27. Hirschmann JV, Raugi GJ,. Lower limb cellulitis and its mimics: part I. Lower limb cellulitis. J Am Acad Dermatol 2012; 67 (2): 163 e1-163 e12; quiz 75-76.
28. Arakaki RY, Strazzula L, Woo E, et al,. The impact of dermatology consultation on diagnostic accuracy and antibiotic use among patients with suspected cellulitis seen at outpatient internal medicine offices: a randomized clinical trial. JAMA Dermatol 2014; 150: 1056-1061.
29. Linscheid P, Seboek D, Schaer DJ, et al,. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 2004; 32 (8): 1715-1721.
30. Schuetz P, Muller B, Christ-Crain M, et al,. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; (9): CD007498.
31. Schuetz P, Christ-Crain M, Muller B,. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections-hope for hype? Swiss Med Wkly 2009; 139 (23-24): 318-326.
32. Jones AE, Fiechtl JF, Brown MD, et al,. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med 2007; 50 (1): 34-41.
33. Muller F, Christ-Crain M, Bregenzer T, et al,. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010; 138 (1): 121-129.
34. Schuetz P, Mueller B, Trampuz A,. Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. Infection 2007; 35 (5): 352-355.
35. Wacker C, Prkno A, Brunkhorst FM, et al,. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13: 426-435.
36. Schuetz P, Chiappa V, Briel M, et al,. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011; 171 (15): 1322-1331.
37. Auriti C, Fiscarelli E, Ronchetti MP, et al,. Procalcitonin in detecting neonatal nosocomial sepsis. Arch Dis Child Fetal Neonatal Ed 2012; 97 (5): F368-F370.
38. Schuetz P, Maurer P, Punjabi V, et al,. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 2013; 17 (3): R115.